ALLR FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – ALLR

Core Points - Rosen Law Firm is reminding purchasers of Allarity Therapeutics, Inc. securities about the lead plaintiff deadline of November 12, 2024, for a class action lawsuit [1] - Investors who purchased Allarity securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm [3] Case Details - The lawsuit alleges that Allarity and its former officers made false and misleading statements regarding the regulatory prospects of Dovitinib, a drug candidate for renal cell carcinoma [5] - It is claimed that Allarity engaged in improper conduct related to the Dovitinib new drug application and premarket approval application, leading to increased regulatory scrutiny and potential legal repercussions [5] - The lawsuit asserts that Allarity downplayed the likelihood of enforcement actions following an investigation into its conduct, resulting in materially false public statements [5]